Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2018
At a glance
- Drugs MAGE A3 6 specific t cells (Primary) ; NTBI 1301 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Adaptimmune
- 07 May 2018 Status changed from active, no longer recruiting to discontinued due to lack of enrollement.
- 13 Mar 2017 Planned primary completion date changed from 1 May 2021 to 1 May 2018.
- 07 Dec 2016 Status changed from recruiting to active, no longer recruiting.